10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended: December 31, 2018
or
¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from _________________ to _________________
	Commission File Number: 000-55403

APPYEA, INC.

(Exact name of registrant as specified in its charter)

  

South Dakota	46-1496846
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
777 Main Street, Suite 600, Fort Worth, Texas	76102
(Address of principal executive offices)	(Zip Code)

 

(817) 887-8142

(Registrant’s telephone number, including area code)

____________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x YES    ¨ NO 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ¨ YES    x NO 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
		Emerging growth company	¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ¨ YES    x NO 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ¨ YES    ¨ NO 

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

2,150,441,260 common shares issued and outstanding as of February 14, 2019

FORM 10-Q

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18
Item 4.	Controls and Procedures	18
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	Defaults Upon Senior Securities	20
Item 4.	Mine Safety Disclosures	20
Item 5.	Other Information	20
Item 6.	Exhibits	21
SIGNATURES		22

2

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

APPYEA, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	December 31,			June 30,
	2018			2018
ASSETS
Current Assets:
Cash and cash equivalents	$	2,064		$	47,196
Total Current Assets		2,064			47,196
Fixed assets, net of accumulated depreciation of $257,070 and $250,570		800			7,300
TOTAL ASSETS	$	2,864		$	54,496
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities		270,221			275,312
Accrued salary		272,000			224,000
Convertible loans and accrued interest, net of unamortized discounts of $37,095 and $81,968, respectively		337,531			290,823
Convertible loans and accrued interest - related party		9,999			8,977
Due to related party		82,689			88,087
Derivative liability		566,519			1,016,865
Total Current Liabilities		1,538,959			1,904,064
Total Liabilities		1,538,959			1,904,064
Stockholders' Deficit:
Convertible preferred stock, $0.0001 par value, 60,000,000 shares authorized, 5,000,000 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively		500			500
Common stock, $0.0001 par value, 6,000,000,000 shares authorized, 1,623,141,260 and 1,240,477,060 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively		162,313			124,047
Additional paid-in capital		4,826,005			4,740,277
Stock payable		62,727			62,727
Accumulated deficit		(6,587,640	)		(6,777,119	)
Total Stockholders' Deficit		(1,536,095	)		(1,849,568	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	2,864		$	54,496

See accompanying notes to the unaudited consolidated financial statements.

3

APPYEA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended						Six months ended
	December 31,						December 31,
	2018			2017			2018			2017
Revenues	$	119		$	110		$	197		$	1,044
Operating Expenses
Legal and professional fees		18,610			164,974			28,171			229,804
General and administrative		26,412			37,860			54,669			135,096
Depreciation		-			7,936			6,500			18,744
Total Operating Expenses		45,022			210,770			89,340			383,644
Loss from operations		(44,903	)		(210,660	)		(89,143	)		(382,600	)
Other Income (Expense)
Change in fair value of derivative liabilities		486,086			(215,751	)		355,325			(349,988	)
Interest expense		(34,128	)		(111,100	)		(76,703	)		(211,556	)
Net Other Income (Expense)		451,958			(326,851	)		278,622			(561,544	)
Net Income (Loss)	$	407,055		$	(537,511	)	$	189,479		$	(944,144	)
Net Income (Loss) Per Common Share:
Basic	$	0.00		$	(0.00	)	$	0.00		$	(0.00	)
Diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(000	)
Weighted Average Number of Common Shares Outstanding:
Basic		1,330,983,536			944,991,968			1,285,730,298			805,777,397
Diluted		7,173,042,878			944,991,968			7,148,481,669			805,777,397

See accompanying notes to the unaudited consolidated financial statements.

4

APPYEA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Six months ended
	December 31,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$	189,479		$	(944,144	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation expense		6,500			18,744
Common stock issued for services		-			99,500
Amortization of debt discounts		44,873			171,514
Change in fair value of derivative liabilities		(355,325	)		349,988
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		(5,091	)		95,196
Accrued salary		48,000			48,000
Accrued interest		31,830			40,043
Net Cash Used in Operating Activities		(39,734	)		(121,159	)
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in equity method investee		-			(25,000	)
Net cash used in Investing Activities		-			(25,000	)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock for cash and common stock payable		-			200
Proceeds from convertible notes payable, net of original issue discounts		-			91,667
Proceeds from convertible notes payable - related party, net of original issue discounts		-			8,333
Proceeds from loan to related party		4,196			20,050
Repayment of loan to related party		(9,594	)		(6,571	)
Net cash provided by (used in) Financing Activities		(5,398	)		113,679
Net cash decrease for period		(45,132	)		(32,480	)
Cash at beginning of period		47,196			42,567
Cash at end of period	$	2,064		$	10,087
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	-
NON CASH INVESTING AND FINANCING ACTIVITIES
Issuance of common stock for conversion of debt and accrued interest	$	28,973		$	145,039
Resolution of derivative liability upon conversion of debt	$	95,021		$	258,603
Derivative liability recognized as debt discount	$	-		$	235,000

See accompanying notes to the unaudited consolidated financial statements.

5

APPYEA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018

(Unaudited)

1. NATURE OF OPERATIONS

AppYea, Inc. ("AppYea", "the Company", "we" or "us") was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and a limited operating history.

The Company incorporated a wholly-owned subsidiary, “AppYea Holdings, Inc.” in state of South Dakota on January 13, 2017 and "The Diagnostic Centers Inc." in State of South Dakota on August 2, 2017.

Through its wholly owned subsidiary, The Diagnostic Centers, Inc., AppYea markets comprehensive diagnostic testing services to physician offices, clinics, hospitals, long term care facilities, healthcare groups, and other healthcare providers.

The Company's common stock is traded on the OTC Markets (www.otcmarkets.com) under the symbol "APYP". The first day of trading on the OTC Markets was December 15, 2014.

2. SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.

In the opinion of the company’s management, the accompanying unaudited interim financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the company as of December 31, 2018 and the results of operations and cash flows for the periods presented. The results of operations for the six months ended December 31, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited financial statements should be read in conjunction with the financial statements and related notes thereto included in the company’s Annual Report on Form 10-K for the year ended June 30, 2018 filed with the SEC on October 15, 2018.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions about the valuation and recognition of stock-based compensation expense, the valuation and recognition of derivative liability, valuation allowance for deferred tax assets and useful life of fixed assets.

Principles of Consolidation

The consolidated financial statements include the accounts of AppYea and its subsidiaries. Intercompany transactions and balances have been eliminated.

Fair Value of Financial Instruments

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

6

The following table summarizes fair value measurements by level at December 31, 2018 and June 30, 2018, measured at fair value on a recurring basis:

December 31, 2018	Level 1		Level 2		Level 3		Total
Assets
None	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	-	$	-	$	566,519	$	566,519

June 30, 2018	Level 1		Level 2		Level 3		Total
Assets
None	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	-	$	-	$	1,016,865	$	1,016,865

3. GOING CONCERN AND LIQUIDITY

At December 31, 2018, the Company had cash of $2,064 and current liabilities of $1,538,959 and a working capital deficit of $1,536,895. The Company has generated net losses from operations since inception. The Company anticipates future losses in its business. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed.

4. FIXED ASSETS

As at December 31, 2018 and June 30, 2018, the balance of fixed assets represented a vehicle and mobile application software as follows:

	December 31			June 30,
	2018			2018
Mobile applications	$	257,870		$	257,870
Accumulated depreciation		(257,070	)		(250,570	)
Fixed assets, net	$	800		$	7,300

Depreciation expense for the six months ended December 31, 2018 and 2017 was $6,500 and $18,744, respectively.

7

5. CONVERTIBLE LOANS

At December 31, 2018 and June 30, 2018, convertible loans consisted of the following:

	December 31,			June 30,
	2018			2018
March 2015 Note	$	-		$	-
November 2016 Note -1		150,000			150,000
Convertible notes - Issued in fiscal year 2018		188,996			195,614
Total convertible notes payable		338,996			345,614
Accrued interest		35,630			27,177
Less: Unamortized debt discount		(37,095	)		(81,968	)
Total convertible notes		337,531			290,823
Less: current portion of convertible notes		337,531			290,823
Long-term convertible notes	$	-		$	-

During the six months ended December 31, 2018 and 2017, the Company recognized amortization of discount, included in interest expense, of $44,873 and $169,442, respectively.

Conversion

During the six months ended December 31, 2018, the Company converted notes with principal amounts and accrued interest of $28,973 into 382,664,200 shares of common stock. The corresponding derivative liability at the date of conversion of $95,021 was settled through additional paid in capital.

March 2015 Note

As of December 31, 2018, and June 30, 2018, the outstanding principal balance of the note was $0, the note had accrued interest of $454.

November 2016 Note 1

On November 15, 2016, the Company entered into four separate agreements with Greentree Financial Group, Inc., consisting of a Financial Advisory Agreement, a Loan Agreement, a Convertible Promissory Note, and a Warrant.

The Loan Agreement allows for the Company to borrow up to $250,000 from Greentree, which will be evidenced by various promissory notes, which will automatically mature 12 months from the date of applicable Note, will accrue interest at a rate of 12% per annum, and will include an original issuance discount (“OID”) of 10%. In addition, the promissory notes will be convertible at a price equal to 55% of the lowest trading price during the 10 trading days immediately prior to a conversion date. The conversion price shall not be lower than $0.0001. Note may not be converted prior to 6 months from its issuance. There is a 10% prepayment penalty associated with each of the promissory notes. Each promissory note conversion shall result in $1,500 being added to the principal of each promissory note converted. An initial promissory note of $100,000 was issued on November 15, 2016.

The warrant issued to Greentree allows for the purchase of up to 5,000,000 shares of the Company’s common stock for a three year period, expiring on November 15, 2019, with an exercise price of $0.03 per share. The warrants also contain a cashless exercise feature, based on a cashless exercise formula.

The Company determined that the exercise feature of the warrants met the definition of a liability in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity’s Own Stock. The Company will bifurcate the embedded conversion option in the note once the note becomes convertible and account for it as a derivative liability. The fair value of the warrants was recorded as a debt discount being amortized to interest expense over the term of the note.

On January 26, 2017 and June 30, 2017, the Company issued convertible notes of $75,000 and $75,000, respectively, according to the loan agreement on November 15, 2016.

8

Promissory Notes - Issued in fiscal year 2018

During the year ended June 30, 2018, the Company issued a total of $180,614 of notes with the following terms:

· Terms ranging from 6 months to 12 months.

· Annual interest rates of 5% - 12%.

· Convertible at the option of the holders at issuance.

· Conversion prices are typically based on the discounted (35% to 45% discount) average closing prices or lowest trading prices of the Company’s shares during various periods prior to conversion. Certain notes allow for the conversion price to be a floor of $0.0002 per share.

· Certain note allows the principal amount will increase by $15,000 and the discount rate of conversion price will decrease by 15% if the conversion price is less than $$0.01. As a result, the discount rate of conversion price changed from 45% to 60% and the Company recognized the penalty of $15,000 and recorded principal amount of $15,000.

Certain notes allow the Company to redeem the notes at rates ranging from 115% to 150% depending on the redemption date provided that no redemption is allowed after the 180th day. Likewise, the note includes original issue discounts and financing costs totaling to $38,447 and the Company received cash of $142,167. Certain convertible notes of $116,666 are currently in default.

On June 25, 2018, the Company entered into and closed a financing transaction with Bellridge Capital L.P. consisting of a Securities Purchase Agreement, a Secured Convertible Promissory Note, and a Warrant.

The Securities Purchase Agreement provides that Bellridge Capital L.P. would receive a Secured Convertible Promissory Note in an amount of $78,947 in exchange for a funding amount of $78,947, and as additional consideration would also receive a Warrant for the purchase of an additional 394,735,000 shares of common stock. The Convertible Promissory Note will accrue interest at a rate of 5% per annum, default interest at a rate of 24% per annum, and will be convertible at a price equal to the lesser of (i) $0.0002, and (ii) the variable conversion price, which is defined as 65% of the lowest daily VWAP in the twenty (20) Trading Days prior to the Conversion Date . The “market price” is defined as the lowest trading price for the common stock during the twenty-five trading day period ending on the last complete trading day prior to the conversion date. The “trading price” is defined as the lowest trade price on the OTC Pink, OTCQB or applicable trading market. Bellridge Capital L.P. shall not be able to convert the promissory notes in an amount that would result in the beneficial ownership of greater than 4.99% of the outstanding shares of the Company, with the exception that the limitation may be waived by Bellridge Capital L.P. with 61 days prior notice. If, at any time when the note is issued and outstanding, the Company sells or issues shares of common stock for no consideration or for a consideration price per share less than the conversion price in effect on the date of such issuance, the conversion price for the note would be reduced to the amount of the consideration per share received by the Company for such dilutive issuance. If the Company prepays the note on or before 90 days following the date of the note, the Company shall be required to pay 115%, multiplied by the sum of the outstanding principal of the note, plus all accrued and unpaid interest and default interest if any. If the Company prepays the note during the period beginning 91 days and ending 180 days from the issue date of the note, the Company shall be required to pay 120% multiplied by the sum of the then outstanding principal amount of the note, plus accrued and unpaid interest and default interest, if any. If the Company prepays the note during the period beginning after 180 days from the issue date of the note, the Company shall be required to pay 125% multiplied by the sum of the then outstanding principal amount of the note, plus accrued and unpaid interest and default interest, if any.

The warrant issued to Bellridge Capital L.P. allows for the purchase of up to 394,735,000 shares of the Company’s common stock for a three-year period with an exercise price of $0.0002 per share. The warrants also contain a cashless exercise feature, based on a cashless exercise formula. In connection with the Secured Promissory Note, the Company entered into a Security Agreement which grants the Debtor a security interest in all of the assets of the Company.

9

Derivative liabilities

The Company determined that the exercise feature of the warrants met the definition of a liability in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity’s Own Stock. The Company will bifurcate the embedded conversion option in the note once the note becomes convertible and account for it as a derivative liability. The fair value of the warrants was recorded as a debt discount being amortized to interest expense over the term of the note.

The Company valued the conversion features using the Black Scholes valuation model. The fair value of the derivative liability for all the note and warrants that became convertible for the year ended June 30, 2018 amounted to $965,401. $277,167 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $688,234 was recognized as a “day 1” derivative loss.

Warrants

A summary of activity during the six months ended December 31, 2018 follows:

	Warrants Outstanding
	Shares		Weighted Average Exercise Price
Outstanding, June 30, 2018		592,916,818	$	0.0004
Granted		-		-
Reset feature		-		-
Exercised		-		-
Forfeited/canceled		-		-
Outstanding, December 31, 2018		592,916,818	$	0.0004

The following table summarizes information relating to outstanding and exercisable warrants as of December 31, 2018:

Warrants Outstanding						Warrants Exercisable
Number of Shares		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Number of Shares		Weighted Average Exercise Price
	5,000,000		0.87	$	0.03		5,000,000	$	0.03
	193,181,818		3.79	$	0.0001		193,181,818	$	0.0001
	394,735,000		2.48	$	0.0002		394,735,000	$	0.0002
	592,916,818		2.90	$	0.0004		592,916,818	$	0.0004

6. CONVERTIBLE LOANS – RELATED PARTY

At December 31, 2018 and June 30, 2018, convertible loan – related party consisted of the following:

	December 31,		June 30,
	2018		2018
Convertible notes - related party -Issued in fiscal year 2018		8,333		8,333
Total convertible notes payable		8,333		8,333
Accrued interest -related party		1,666		644
Less: Unamortized debt discount - related party		-		-
Total convertible notes		9,999		8,977
Less: current portion of convertible notes - related party		9,999		8,977
Long-term convertible notes	$	-	$	-

10

During the six months ended December 31, 2018 and 2017, the Company recognized amortization of discount, included in interest expense, of $0 and $2,072, respectively.

Promissory Notes - Issued in fiscal year 2018

During the year ended June 30, 2018, the Company issued a total of $8,333 note with the following terms:

· Terms of 6 months.

· Annual interest rates of 8%.

· Convertible at the option of the holders at issuance.

· Conversion prices are typically based on the discounted (45% discount) average closing prices of the Company’s shares during 20 days prior to conversion.

The Company received cash of $8,333.

The Company determined that the conversion feature met the definition of a liability in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity's Own Stock and therefore bifurcated the embedded conversion option once the note becomes convertible and accounted for it as a derivative liability. The fair value of the conversion feature was recorded as a debt discount and amortized to interest expense over the term of the note.

The Company valued the conversion feature using the Black Scholes valuation model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the year ended June 30, 2018 amounted to $9,371. $8,333 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $1,038 was recognized as a “day 1” derivative loss.

7. DERIVATIVE LIABILITIES

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options.

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of December 31, 2018. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

11

At December 31, 2018, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Six months ended December 31, 2018			Year Ended June 30, 2018
Expected term		0.48 - 4.04 years			0.04 - 5.00 years
Expected average volatility		270%-451	%		147%-488	%
Expected dividend yield		-			-
Risk-free interest rate		2.36%-2.94	%		0.96%-2.73	%

The following table summarizes the changes in the derivative liabilities during the six months ended December 31, 2018:

Fair Value Measurements Using Significant Observable Inputs (Level 3)
Balance - June 30, 2018	$	1,016,865
Settled due to conversion of debt		(95,021	)
Gain on change in fair value of the derivative		(355,325	)
Balance - December 31, 2018	$	566,519

The aggregate (gain) loss on derivatives during the six months ended December 31, 2018 and 2017 was ($355,325) and $349,988, respectively.

8. COMMITMENTS AND CONTINGENCIES

Leases and Long term Contracts

The Company has not entered into any long-term leases, contracts or commitments.

Agreements

In December 2016, the Company entered into a contract agreement with M Endeavors, LLC for marketing the services to Doctors office, clinic and hospitals for the term of 5 years. The Agreements shall automatically renew for successive 12-month periods unless otherwise terminated in accordance with the terms of this Agreement. The Company was required to pay a monthly fee of $8,000 and expenses related to this contract. The Company mutually agreed to terminate this agreement. As of December 31, 2018 and June 30, 2018, the Company recorded accrued expenses of $75,000 and $75,000, respectively.

In December 2016, the Company entered into a contract agreement with Big Dreams ventures, LLC for marketing the services to Doctors office, clinic and hospitals for the term of 5 years. The Agreement shall automatically renew for successive 12-month periods unless otherwise terminated in accordance with the terms of this Agreement. The Company was required to pay a monthly fee of $10,000 and expenses related to this contract. The Company mutually agreed to terminate this agreement. As of December 31, 2018 and June 30, 2018, the Company recorded accrued expenses of $105,250 and $105,250, respectively.

On October 2, 2017, the Company entered into an agreement with Pacific Pain & Regenerative Medicine. The Company was required to pay $3,000 per month for a collector in exchange for a minimum of 5 PGX tests per week or 20 per month. During the year ended June 30, 2018, the Company terminated the services and stopped making the monthly payments. As of December 31, 2018 and June 30, 2018, the Company recorded accrued expense of $21,000 and $21,000, respectively.

On October 17, 2017, the Company entered into an agreement of the acquisition financing of up to $30,000,000 (“the “Placement’) with Wellington Shields $ Co. The Company shall pay (i) a success fee equal to 8% of the gross proceeds of the Placement, (ii) 3% of the total Company’s shares outstanding at the time of closing the placement, and (iii) was required to pay $15,000 at the time of signing and $10,000 per month. This engagement agreement terminated at the close of business April 30, 2018. As of December 31, 2018 and June 30, 2018, the Company recorded accrued expense of $60,000 and $60,000, respectively.

Rent

As of January 30, 2013, the Company leases office space at $200 per month with three-month terms, which shall be automatically extended for successive three-month periods unless there is the notice to cancel. The lease can be cancelled at any time by either party with 30 days’ notice prior to expiration of an applicable term. For the six months ended December 31, 2018 and 2017, the Company incurred $1,246 and $1,238, respectively.

12

9. SHAREHOLDERS' EQUITY

Series A Preferred Stock

The Company is authorized to issue 60,000,000 shares of Series A Preferred Stock at a par value of $0.0001.

Each Series A preferred share is convertible into 1,500 shares of common stock and has the voting rights of 1,000 shares of common stock.

As at December 31, 2018 and June 30, 2018, 5,000,000 shares of the Company's Series A Preferred Stock were issued and outstanding.

Common Stock

During the six months ended December 31, 2018, the Company issued 382,664,200 shares of common stock for conversion of debt and accrued interest of $28,973.

As at December 31, 2018 and June 30, 2018, 1,623,141,260 and 1,240,477,060 shares of the Company's common stock were issued and outstanding.

Stock payable

The Company had insufficient authorized shares as of June 30, 2017 and as a result, the Company had $105,000 in stock payable for which it is obligated to issue 55,000,000 shares of common stock for consulting services. During the year ended June 30, 2018 the company issued 30,000,000 common shares for cash of $200 and reduced common stock payable by $57,273.

As of December 31, 2018, the Company had $47,727 in stock payable for which it is obligated to issue 25,000,000 shares of common stock for consulting services.

On November 13, 2017, the Company entered into a consulting agreement with a third party for the term of 5 years with a consideration of an issuance of 40,000,000 shares of common stock valued at $20,000. The share shall be issued in two tranches with first tranche of 10,000,000 shares being due at signing of this agreement and an additional 30,000,000 shares are due on the 3 months anniversary of this agreement. During the year ended June 30, 2018, the Company issued 10,000,000 shares with a fair value of $5,000. As of December 31, 2018, the Company had $15,000 in stock payable for which it is obligated to issue 30,000,000 shares of common stock for consulting services.

10. RELATED PARTY TRANSACTIONS

In March 2016, the Company appointed current CEO and approved a base compensation package of $8,000 per month for CEO. As of December 31, 2018, and June 30, 2018, the Company recorded accrued salary of $272,000 and $224,000, respectively.

During the six months ended December 31, 2018 and 2017, the Company borrowed a total amount of $4,196 and $20,050 from Evergreen Venture Partners LLC (“EVP”), which the CEO is the majority owner, and repaid $9,594 and $6,571, respectively. This loan is a non-interest bearing and due on demand. As of December 31, 2018, and June 30, 2018, the Company owed EVP, a related party $82,689 and $88,087, respectively.

13

11. EARNING (LOSS) PER SHARE The following is a reconciliation of the numerator and denominator used in the basic and diluted earnings per share ("EPS") calculations.

	Three Months Ended						Six months ended
	December 31,						December 31,
	2018			2017			2018			2017
Numerator:
Net income (loss)	$	407,055		$	(537,511	)	$	189,479		$	(944,144	)
Earnings allocated to participating securities		(451,958	)		-			(278,622	)		-
Income (loss) available to common stockholders	$	(44,903	)	$	(537,511	)	$	(89,143	)	$	(944,144	)
Denominator:
Weighted-average shares of common stock		1,330,983,536			944,991,968			1,285,730,298			805,777,397
Dilutive effect of convertible instruments		5,614,029,126			-			5,614,029,126			-
Dilutive effect of outstanding warrants		228,030,216			-			248,722,245			-
Diluted weighted-average of common stock		7,173,042,878			944,991,968			7,148,481,669			805,777,397
Net income (loss) per common share from:
Basic:	$	0.00		$	(0.00	)	$	0.00		$	(0.00	)
Diluted:	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

For the periods ended December 31, 2017, the convertible instruments are anti-dilutive and therefore, have been excluded from earnings (loss) per share.

For the periods ended December 31, 2018, diluted earnings per share is calculated using net income available to common stockholders divided by the diluted weighted average number of common shares outstanding during each period determined using the treasury stock method and the if-converted method.

12. SUBSEQUENT EVENTS

Subsequent to December 31, 2018, the Company issued 527,300,000 shares of common stock for conversion of debt and accrued interest of $25,448.

14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report and unless otherwise indicated, the terms “we”, “us”, and “our” mean AppYea, Inc., and our wholly owned subsidiaries, AppYea Holdings, Inc., a South Dakota corporation and The Diagnostic Centers, Inc., a South Dakota corporation unless otherwise indicated.

General Overview

We were incorporated in the State of South Dakota on November 26, 2012. We are engaged in the acquisition, purchase, maintenance and creation of mobile software applications.

We are an early stage company that was initially only engaged in the acquisition, purchase, and maintenance of mobile software applications (“apps”). Although we are still active in the mobile applications industry, we began investigating healthcare markets to augment the apps business in early 2017 and subsequently formed a wholly owned subsidiary The Diagnostic Centers, Inc. to focus on marketing certain products and services to healthcare providers.

On November 15, 2017, we entered into a distribution agreement with Cedar Creek Labs Series Two LLC (“LLC”) for the term of 1 year. The agreement shall be automatically extended for successive 1 year unless there is the notice to terminate. Our Company shall use best efforts to market the Products for the LLC and will receive compensation ranging from 15% to 40% of profit. Our company owns membership interests of 5% in LLC and the transactions between our company and LLC which is an equity method investee are deemed to be between related parties. The Company reviewed Cedar Creek Labs Series Two LLC financial condition at June 30, 2018 and concluded that there is a 100% impairment loss related to the Company’s investment, and recorded an impairment loss of $24,524, for the year ended June 30, 2018.

Our administrative office is located at 777 Main Street, Suite 600, Fort Worth, TX 76102, Telephone: (817) 887-8142. Our corporate website is www.appyea.com.

Our fiscal year end is June 30th. We have not been subject to any bankruptcy, receivership or similar proceeding.

We have two wholly owned subsidiaries, AppYea Holdings, Inc., a South Dakota corporation and The Diagnostic Centers, Inc., a South Dakota corporation.

15

Results of Operations

Three months ended December 31, 2018 compared to three months ended December 31, 2017.

	Three Months Ended
	December 31,
	2018			2017
Revenue	$	119		$	110
Operating expenses	$	(45,022	)	$	(210,770	)
Other income (expense)	$	451,958		$	(326,851	)
Net income (loss)	$	407,055		$	(537,511	)

We generated revenues of $119 for the three months ended December 31, 2018, compared to revenues of $110 for the same period in 2017.

Our operating expenses, for the three months ended December 31, 2018 were $45,022 compared to $210,770 for the same period in 2017. The decrease in operating expenses was primarily as a result of decrease in consulting expense.

Other net income, for the three months ended December 31, 2018 was $451,958 compared to other expense of $326,851 for the same period in 2017. The increase in other income was primarily related to change in fair value of derivative liabilities.

We incurred a net income (loss) of $407,055 and ($537,511) for the three months ended December 31, 2018 and 2017, respectively.

Six months ended December 31, 2018 compared to six months ended December 31, 2017.

	Six months ended
	December 31,
	2018			2017
Revenue	$	197		$	1,044
Operating expenses	$	(89,340	)	$	(383,644	)
Other income (expense)	$	278,622		$	(561,544	)
Net income (loss)	$	189,479		$	(944,144	)

We generated revenues of $197 for the six months ended December 31, 2018, compared to revenues of $1,044 for the same period in 2017.

Our operating expenses, for the six months ended December 31, 2018 were $89,340 compared to $383,644 for the same period in 2017. The decrease in operating expenses, for 2018, was primarily as a result of decrease in consulting expenses and settlement expense that occurred in 2017.

Other net income, for the six months ended December 31, 2018 was $278,622 compared to other expense of $561,544 for the same period in 2017. The increase in other expenses was primarily related to change in fair value of derivative liabilities.

We incurred a net income of $189,479 and net loss of $944,144 for the six months ended December 31, 2018 and 2017, respectively.

16

Liquidity and Capital Resources

The following table provides selected financial data about our company as of December 31, 2018 and June 30, 2018, respectively.

Working Capital

	December 31,			June 30,
	2018			2018
Cash	$	2,064		$	47,196
Current Assets	$	2,064		$	47,196
Current Liabilities	$	1,538,959		$	1,904,064
Working Capital (Deficiency)	$	(1,536,895	)	$	(1,856,868	)

Cash Flows

	Six months ended
	December 31,
	2018			2017
Cash Flows Used In Operating Activities	$	(39,734	)	$	(121,159	)
Cash Flows Used In Investing Activities	$	-		$	(25,000	)
Cash Flows From (Used in) Financing Activities	$	(5,398	)	$	113,679
Net Change In Cash During Period	$	(45,132	)	$	(32,480	)

As at December 31, 2018 our company’s cash balance was $2,064 and total assets were $2,864. As at June 30, 2018, our company’s cash balance was $47,196 and total assets were $54,496.

As at December 31, 2018, our company had total liabilities of $1,538,959, compared with total liabilities of $1,904,064 as at June 30, 2018.

As at December 31, 2018, our company had a working capital deficiency of $1,536,895 compared with working capital deficiency of $1,856,868 as at June 30, 2018. The decrease in working capital deficiency was primarily attributed to a decrease in derivative liabilities.

Cash Flow from Operating Activities

During the six months ended December 31, 2018, our company used $39,734 in cash from operating activities, compared to $121,159 cash used in operating activities during the six months ended December 31, 2017. During the six months ended December 31, 2018, we incurred a net income of $189,479 of which $355,325 arose from non-cash income from change in derivative valuations and $51,373 arose from non-cash expenses and we generated cash flows of $74,739 from the net increase in operating liabilities. During the six months ended December 31, 2017 we incurred a net loss of $944,144 of which $639,746 arose from non-cash expenses and we generated cash flows of $183,239 from the net increase in current liabilities.

Cash Flow from Investing Activities

During the six months ended December 31, 2018 and 2017, our company used $0 for investment in equity method investee and $25,000, respectively

Cash Flow from Financing Activities

During the six months ended December 31, 2018, our company used $5,398 in financing activities compared to $113,679 received from financing activities during the six months ended December 31, 2017. During the six months ended December 31, 2018, we received $4,196 loan from a related party and repaid $9,594 to a related party. During the six months ended December 31, 2017, we received $91,667 by way of loan under a convertible note payable, $8,333 by way of loan under a convertible note payable – related party, $200 from the issuance of our common shares, $20,050 loan from a related party and repaid $6,571 to a related party.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.

17

Critical Accounting Policies

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Financial Instruments 

Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. ASC 820-10 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. FASB ASC 820 establishes a fair value hierarchy that prioritizes the use of inputs used in valuation methodologies into the following three levels:

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs that reflect a reporting entity's own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

The carrying values of cash, accounts receivable, prepaid expenses, accounts payable, and accruals approximate their fair value due to the short-term maturities of these instruments.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s management conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) under the 1934 Act) pursuant to Rule 13a-15 under the 1934 Act. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports it files or submits under the 1934 Act is recorded, processed, summarized and reported on a timely basis and that such information is communicated to management and the Company’s board of directors to allow timely decisions regarding required disclosure.

18

Based on this evaluation, it has been concluded that the design and operation of our disclosure controls and procedures are not effective since the following material weaknesses exist:

· Since inception our chief executive officer also functions as our chief financial officer. As a result, our officers may not be able to identify errors and irregularities in the financial statements and reports.

· We were unable to maintain full segregation of duties within our financial operations due to our reliance on limited personnel in the finance function. While this control deficiency did not result in any material adjustments to our financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties.

· Documentation of all proper accounting procedures is not yet complete.

To the extent reasonably possible given our limited resources, as financial resources become available we intend to take measures to cure the aforementioned weaknesses, including, but not limited to, the following:

· Increasing the capacity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across the organization and that we have adequate control over financial statement disclosures.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

19

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

To the best of the Company’s knowledge and belief, no legal proceedings are currently pending or threatened.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

20

Item 6. Exhibits

Exhibit Number	Description
(31)	Rule 13a-14 (d)/15d-14d) Certifications
31.1*	Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)	Section 1350 Certifications
32.1**	Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101*	Interactive Data File
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

__________ 

* Filed herewith.

** Furnished herewith.

21

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	APPYEA, INC.
	(Registrant)
Dated: February 19, 2019	/s/ Douglas O. McKinnon
	Douglas O. McKinnon
	Chief Executive Officer and Chief Financial Officer
	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

22

EX-31.1

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Douglas O. McKinnon, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Appyea, Inc.;
2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  February 19, 2019

/s/ Douglas O. McKinnon

Douglas O. McKinnon

Chief Executive Officer and Chief Financial Officer

(Principal Executive Officer,

Principal Financial Officer and Principal Accounting Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Douglas O. McKinnon, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	the Quarterly Report on Form 10-Q of Appyea, Inc. for the period ended December 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Appyea, Inc.

Dated: February 19, 2019	/s/ Douglas O. McKinnon
	Douglas O. McKinnon
	Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
	Appyea, Inc.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Appyea, Inc. and will be retained by Appyea, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2018	Feb. 14, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	APPYEA, INC
Entity Central Index Key	0001568969
Trading Symbol	apyp
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		2,150,441,260
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false

XML

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Current Assets:
Cash and cash equivalents	$ 2,064	$ 47,196
Total Current Assets	2,064	47,196
Fixed assets, net of accumulated depreciation of $257,070 and $250,570	800	7,300
TOTAL ASSETS	2,864	54,496
Current Liabilities:
Accounts payable and accrued liabilities	270,221	275,312
Accrued salary	272,000	224,000
Convertible loans and accrued interest, net of unamortized discounts of $37,095 and $81,968, respectively	337,531	290,823
Convertible loans and accrued interest - related party	9,999	8,977
Due to related party	82,689	88,087
Derivative liability	566,519	1,016,865
Total Current Liabilities	1,538,959	1,904,064
Total Liabilities	1,538,959	1,904,064
Stockholders' Deficit:
Convertible preferred stock, $0.0001 par value, 60,000,000 shares authorized, 5,000,000 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively	500	500
Common stock, $0.0001 par value, 6,000,000,000 shares authorized, 1,623,141,260 and 1,240,477,060 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively	162,313	124,047
Additional paid-in capital	4,826,005	4,740,277
Stock payable	62,727	62,727
Accumulated deficit	(6,587,640)	(6,777,119)
Total Stockholders' Deficit	(1,536,095)	(1,849,568)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 2,864	$ 54,496

XML

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Statement of Financial Position [Abstract]
Accumulated depreciation of fixed assets (in dollars)	$ 257,070	$ 250,570
Convertible loans and accrued interest, unamortized discounts (in dollars)	$ 37,095	$ 81,968
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	60,000,000	60,000,000
Convertible preferred stock, shares issued	5,000,000	5,000,000
Convertible preferred stock, shares outstanding	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	6,000,000,000	6,000,000,000
Common stock, shares issued	1,623,141,260	1,240,477,060
Common stock, shares outstanding	1,623,141,260	1,240,477,060

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenues	$ 119	$ 110	$ 197	$ 1,044
Operating Expenses
Legal and professional fees	18,610	164,974	28,171	229,804
General and administrative	26,412	37,860	54,669	135,096
Depreciation		7,936	6,500	18,744
Total Operating Expenses	45,022	210,770	89,340	383,644
Loss from operations	(44,903)	(210,660)	(89,143)	(382,600)
Other Income (Expense)
Change in fair value of derivative liabilities	486,086	(215,751)	355,325	(349,988)
Interest expense	(34,128)	(111,100)	(76,703)	(211,556)
Net Other Income (Expense)	451,958	(326,851)	278,622	(561,544)
Net Income (Loss)	$ 407,055	$ (537,511)	$ 189,479	$ (944,144)
Net Income (Loss) Per Common Share:
Basic (in dollars per share)	$ 0.00	$ (0.00)	$ 0.00	$ (0.00)
Diluted (in dollars per share)	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted Average Number of Common Shares Outstanding:
Basic (in shares)	1,330,983,536	944,991,968	1,285,730,298	805,777,397
Diluted (in shares)	7,173,042,878	944,991,968	7,148,481,669	805,777,397

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ 189,479	$ (944,144)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation expense	6,500	18,744
Common stock issued for services		99,500
Amortization of debt discounts	44,873	171,514
Change in fair value of derivative liabilities	(355,325)	349,988
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	(5,091)	95,196
Accrued salary	48,000	48,000
Accrued interest	31,830	40,043
Net Cash Used in Operating Activities	(39,734)	(121,159)
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in equity method investee		(25,000)
Net cash used in Investing Activities		(25,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock for cash and common stock payable		200
Proceeds from convertible notes payable, net of original issue discounts		91,667
Proceeds from convertible notes payable - related party, net of original issue discounts		8,333
Proceeds from loan to related party	4,196	20,050
Repayment of loan to related party	(9,594)	(6,571)
Net cash provided by (used in) Financing Activities	(5,398)	113,679
Net cash decrease for period	(45,132)	(32,480)
Cash at beginning of period	47,196	42,567
Cash at end of period	2,064	10,087
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	0	0
Cash paid for interest	0	0
NON CASH INVESTING AND FINANCING ACTIVITIES
Issuance of common stock for conversion of debt and accrued interest	28,973	145,039
Resolution of derivative liability upon conversion of debt	$ 95,021	258,603
Derivative liability recognized as debt discount		$ 235,000

XML

NATURE OF OPERATIONS

6 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

1. NATURE OF OPERATIONS

AppYea, Inc. ("AppYea", "the Company", "we" or "us") was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and a limited operating history.

The Company incorporated a wholly-owned subsidiary, “AppYea Holdings, Inc.” in state of South Dakota on January 13, 2017 and "The Diagnostic Centers Inc." in State of South Dakota on August 2, 2017.

Through its wholly owned subsidiary, The Diagnostic Centers, Inc., AppYea markets comprehensive diagnostic testing services to physician offices, clinics, hospitals, long term care facilities, healthcare groups, and other healthcare providers.

The Company's common stock is traded on the OTC Markets (www.otcmarkets.com) under the symbol "APYP". The first day of trading on the OTC Markets was December 15, 2014.

XML

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

2. SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.

In the opinion of the company’s management, the accompanying unaudited interim financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the company as of December 31, 2018 and the results of operations and cash flows for the periods presented. The results of operations for the six months ended December 31, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited financial statements should be read in conjunction with the financial statements and related notes thereto included in the company’s Annual Report on Form 10-K for the year ended June 30, 2018 filed with the SEC on October 15, 2018.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions about the valuation and recognition of stock-based compensation expense, the valuation and recognition of derivative liability, valuation allowance for deferred tax assets and useful life of fixed assets.

Principles of Consolidation

The consolidated financial statements include the accounts of AppYea and its subsidiaries. Intercompany transactions and balances have been eliminated.

Fair Value of Financial Instruments

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The following table summarizes fair value measurements by level at December 31, 2018 and June 30, 2018, measured at fair value on a recurring basis:

December 31, 2018	Level 1		Level 2		Level 3		Total
Assets
None	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	-	$	-	$	566,519	$	566,519

June 30, 2018	Level 1		Level 2		Level 3		Total
Assets
None	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	-	$	-	$	1,016,865	$	1,016,865

XML

GOING CONCERN AND LIQUIDITY

6 Months Ended

Dec. 31, 2018

Going Concern And Liquidity [Abstract]

GOING CONCERN AND LIQUIDITY

3. GOING CONCERN AND LIQUIDITY

At December 31, 2018, the Company had cash of $2,064 and current liabilities of $1,538,959 and a working capital deficit of $1,536,895. The Company has generated net losses from operations since inception. The Company anticipates future losses in its business. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed.

XML

FIXED ASSETS

6 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

FIXED ASSETS

4. FIXED ASSETS

As at December 31, 2018 and June 30, 2018, the balance of fixed assets represented a vehicle and mobile application software as follows:

	December 31			June 30,
	2018			2018
Mobile applications	$	257,870		$	257,870
Accumulated depreciation		(257,070	)		(250,570	)
Fixed assets, net	$	800		$	7,300

Depreciation expense for the six months ended December 31, 2018 and 2017 was $6,500 and $18,744, respectively.

XML

CONVERTIBLE LOANS

6 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

CONVERTIBLE LOANS

5. CONVERTIBLE LOANS

At December 31, 2018 and June 30, 2018, convertible loans consisted of the following:

	December 31,			June 30,
	2018			2018
March 2015 Note	$	-		$	-
November 2016 Note -1		150,000			150,000
Convertible notes - Issued in fiscal year 2018		188,996			195,614
Total convertible notes payable		338,996			345,614
Accrued interest		35,630			27,177
Less: Unamortized debt discount		(37,095	)		(81,968	)
Total convertible notes		337,531			290,823
Less: current portion of convertible notes		337,531			290,823
Long-term convertible notes	$	-		$	-

During the six months ended December 31, 2018 and 2017, the Company recognized amortization of discount, included in interest expense, of $44,873 and $169,442, respectively.

Conversion

During the six months ended December 31, 2018, the Company converted notes with principal amounts and accrued interest of $28,973 into 382,664,200 shares of common stock. The corresponding derivative liability at the date of conversion of $95,021 was settled through additional paid in capital.

March 2015 Note

As of December 31, 2018, and June 30, 2018, the outstanding principal balance of the note was $0, the note had accrued interest of $454.

November 2016 Note 1

On November 15, 2016, the Company entered into four separate agreements with Greentree Financial Group, Inc., consisting of a Financial Advisory Agreement, a Loan Agreement, a Convertible Promissory Note, and a Warrant.

The Loan Agreement allows for the Company to borrow up to $250,000 from Greentree, which will be evidenced by various promissory notes, which will automatically mature 12 months from the date of applicable Note, will accrue interest at a rate of 12% per annum, and will include an original issuance discount (“OID”) of 10%. In addition, the promissory notes will be convertible at a price equal to 55% of the lowest trading price during the 10 trading days immediately prior to a conversion date. The conversion price shall not be lower than $0.0001. Note may not be converted prior to 6 months from its issuance. There is a 10% prepayment penalty associated with each of the promissory notes. Each promissory note conversion shall result in $1,500 being added to the principal of each promissory note converted. An initial promissory note of $100,000 was issued on November 15, 2016.

The warrant issued to Greentree allows for the purchase of up to 5,000,000 shares of the Company’s common stock for a three year period, expiring on November 15, 2019, with an exercise price of $0.03 per share. The warrants also contain a cashless exercise feature, based on a cashless exercise formula.

The Company determined that the exercise feature of the warrants met the definition of a liability in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity’s Own Stock. The Company will bifurcate the embedded conversion option in the note once the note becomes convertible and account for it as a derivative liability. The fair value of the warrants was recorded as a debt discount being amortized to interest expense over the term of the note.

On January 26, 2017 and June 30, 2017, the Company issued convertible notes of $75,000 and $75,000, respectively, according to the loan agreement on November 15, 2016.

Promissory Notes - Issued in fiscal year 2018

During the year ended June 30, 2018, the Company issued a total of $180,614 of notes with the following terms:

· Terms ranging from 6 months to 12 months.

· Annual interest rates of 5% - 12%.

· Convertible at the option of the holders at issuance.

· Conversion prices are typically based on the discounted (35% to 45% discount) average closing prices or lowest trading prices of the Company’s shares during various periods prior to conversion. Certain notes allow for the conversion price to be a floor of $0.0002 per share.

· Certain note allows the principal amount will increase by $15,000 and the discount rate of conversion price will decrease by 15% if the conversion price is less than $$0.01. As a result, the discount rate of conversion price changed from 45% to 60% and the Company recognized the penalty of $15,000 and recorded principal amount of $15,000.

Certain notes allow the Company to redeem the notes at rates ranging from 115% to 150% depending on the redemption date provided that no redemption is allowed after the 180th day. Likewise, the note includes original issue discounts and financing costs totaling to $38,447 and the Company received cash of $142,167. Certain convertible notes of $116,666 are currently in default.

On June 25, 2018, the Company entered into and closed a financing transaction with Bellridge Capital L.P. consisting of a Securities Purchase Agreement, a Secured Convertible Promissory Note, and a Warrant.

The Securities Purchase Agreement provides that Bellridge Capital L.P. would receive a Secured Convertible Promissory Note in an amount of $78,947 in exchange for a funding amount of $78,947, and as additional consideration would also receive a Warrant for the purchase of an additional 394,735,000 shares of common stock. The Convertible Promissory Note will accrue interest at a rate of 5% per annum, default interest at a rate of 24% per annum, and will be convertible at a price equal to the lesser of (i) $0.0002, and (ii) the variable conversion price, which is defined as 65% of the lowest daily VWAP in the twenty (20) Trading Days prior to the Conversion Date . The “market price” is defined as the lowest trading price for the common stock during the twenty-five trading day period ending on the last complete trading day prior to the conversion date. The “trading price” is defined as the lowest trade price on the OTC Pink, OTCQB or applicable trading market. Bellridge Capital L.P. shall not be able to convert the promissory notes in an amount that would result in the beneficial ownership of greater than 4.99% of the outstanding shares of the Company, with the exception that the limitation may be waived by Bellridge Capital L.P. with 61 days prior notice. If, at any time when the note is issued and outstanding, the Company sells or issues shares of common stock for no consideration or for a consideration price per share less than the conversion price in effect on the date of such issuance, the conversion price for the note would be reduced to the amount of the consideration per share received by the Company for such dilutive issuance. If the Company prepays the note on or before 90 days following the date of the note, the Company shall be required to pay 115%, multiplied by the sum of the outstanding principal of the note, plus all accrued and unpaid interest and default interest if any. If the Company prepays the note during the period beginning 91 days and ending 180 days from the issue date of the note, the Company shall be required to pay 120% multiplied by the sum of the then outstanding principal amount of the note, plus accrued and unpaid interest and default interest, if any. If the Company prepays the note during the period beginning after 180 days from the issue date of the note, the Company shall be required to pay 125% multiplied by the sum of the then outstanding principal amount of the note, plus accrued and unpaid interest and default interest, if any.

The warrant issued to Bellridge Capital L.P. allows for the purchase of up to 394,735,000 shares of the Company’s common stock for a three-year period with an exercise price of $0.0002 per share. The warrants also contain a cashless exercise feature, based on a cashless exercise formula. In connection with the Secured Promissory Note, the Company entered into a Security Agreement which grants the Debtor a security interest in all of the assets of the Company.

Derivative liabilities

The Company determined that the exercise feature of the warrants met the definition of a liability in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity’s Own Stock. The Company will bifurcate the embedded conversion option in the note once the note becomes convertible and account for it as a derivative liability. The fair value of the warrants was recorded as a debt discount being amortized to interest expense over the term of the note.

The Company valued the conversion features using the Black Scholes valuation model. The fair value of the derivative liability for all the note and warrants that became convertible for the year ended June 30, 2018 amounted to $965,401. $277,167 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $688,234 was recognized as a “day 1” derivative loss.

Warrants

A summary of activity during the six months ended December 31, 2018 follows:

	Warrants Outstanding
	Shares		Weighted Average Exercise Price
Outstanding, June 30, 2018		592,916,818	$	0.0004
Granted		-		-
Reset feature		-		-
Exercised		-		-
Forfeited/canceled		-		-
Outstanding, December 31, 2018		592,916,818	$	0.0004

The following table summarizes information relating to outstanding and exercisable warrants as of December 31, 2018:

Warrants Outstanding						Warrants Exercisable
Number of Shares		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Number of Shares		Weighted Average Exercise Price
	5,000,000		0.87	$	0.03		5,000,000	$	0.03
	193,181,818		3.79	$	0.0001		193,181,818	$	0.0001
	394,735,000		2.48	$	0.0002		394,735,000	$	0.0002
	592,916,818		2.90	$	0.0004		592,916,818	$	0.0004

XML

CONVERTIBLE LOANS - RELATED PARTY

6 Months Ended

Dec. 31, 2018

Convertible Loans Related Party [Abstract]

CONVERTIBLE LOANS - RELATED PARTY

6. CONVERTIBLE LOANS – RELATED PARTY

At December 31, 2018 and June 30, 2018, convertible loan – related party consisted of the following:

	December 31,		June 30,
	2018		2018
Convertible notes - related party -Issued in fiscal year 2018		8,333		8,333
Total convertible notes payable		8,333		8,333
Accrued interest -related party		1,666		644
Less: Unamortized debt discount - related party		-		-
Total convertible notes		9,999		8,977
Less: current portion of convertible notes - related party		9,999		8,977
Long-term convertible notes	$	-	$	-

During the six months ended December 31, 2018 and 2017, the Company recognized amortization of discount, included in interest expense, of $0 and $2,072, respectively.

Promissory Notes - Issued in fiscal year 2018

During the year ended June 30, 2018, the Company issued a total of $8,333 note with the following terms:

· Terms of 6 months.

· Annual interest rates of 8%.

· Convertible at the option of the holders at issuance.

· Conversion prices are typically based on the discounted (45% discount) average closing prices of the Company’s shares during 20 days prior to conversion.

The Company received cash of $8,333.

The Company determined that the conversion feature met the definition of a liability in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity's Own Stock and therefore bifurcated the embedded conversion option once the note becomes convertible and accounted for it as a derivative liability. The fair value of the conversion feature was recorded as a debt discount and amortized to interest expense over the term of the note.

The Company valued the conversion feature using the Black Scholes valuation model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the year ended June 30, 2018 amounted to $9,371. $8,333 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $1,038 was recognized as a “day 1” derivative loss.

XML

DERIVATIVE LIABILITIES

6 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE LIABILITIES

7. DERIVATIVE LIABILITIES

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options.

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of December 31, 2018. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

At December 31, 2018, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Six months ended December 31, 2018			Year Ended June 30, 2018
Expected term		0.48 - 4.04 years			0.04 - 5.00 years
Expected average volatility		270%-451	%		147%-488	%
Expected dividend yield		-			-
Risk-free interest rate		2.36%-2.94	%		0.96%-2.73	%

The following table summarizes the changes in the derivative liabilities during the six months ended December 31, 2018:

Fair Value Measurements Using Significant Observable Inputs (Level 3)
Balance - June 30, 2018	$	1,016,865
Settled due to conversion of debt		(95,021	)
Gain on change in fair value of the derivative		(355,325	)
Balance - December 31, 2018	$	566,519

The aggregate (gain) loss on derivatives during the six months ended December 31, 2018 and 2017 was ($355,325) and $349,988, respectively.

XML

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

8. COMMITMENTS AND CONTINGENCIES

Leases and Long term Contracts

The Company has not entered into any long-term leases, contracts or commitments.

Agreements

In December 2016, the Company entered into a contract agreement with M Endeavors, LLC for marketing the services to Doctors office, clinic and hospitals for the term of 5 years. The Agreements shall automatically renew for successive 12-month periods unless otherwise terminated in accordance with the terms of this Agreement. The Company was required to pay a monthly fee of $8,000 and expenses related to this contract. The Company mutually agreed to terminate this agreement. As of December 31, 2018 and June 30, 2018, the Company recorded accrued expenses of $75,000 and $75,000, respectively.

In December 2016, the Company entered into a contract agreement with Big Dreams ventures, LLC for marketing the services to Doctors office, clinic and hospitals for the term of 5 years. The Agreement shall automatically renew for successive 12-month periods unless otherwise terminated in accordance with the terms of this Agreement. The Company was required to pay a monthly fee of $10,000 and expenses related to this contract. The Company mutually agreed to terminate this agreement. As of December 31, 2018 and June 30, 2018, the Company recorded accrued expenses of $105,250 and $105,250, respectively.

On October 2, 2017, the Company entered into an agreement with Pacific Pain & Regenerative Medicine. The Company was required to pay $3,000 per month for a collector in exchange for a minimum of 5 PGX tests per week or 20 per month. During the year ended June 30, 2018, the Company terminated the services and stopped making the monthly payments. As of December 31, 2018 and June 30, 2018, the Company recorded accrued expense of $21,000 and $21,000, respectively.

On October 17, 2017, the Company entered into an agreement of the acquisition financing of up to $30,000,000 (“the “Placement’) with Wellington Shields $ Co. The Company shall pay (i) a success fee equal to 8% of the gross proceeds of the Placement, (ii) 3% of the total Company’s shares outstanding at the time of closing the placement, and (iii) was required to pay $15,000 at the time of signing and $10,000 per month. This engagement agreement terminated at the close of business April 30, 2018. As of December 31, 2018 and June 30, 2018, the Company recorded accrued expense of $60,000 and $60,000, respectively.

Rent

As of January 30, 2013, the Company leases office space at $200 per month with three-month terms, which shall be automatically extended for successive three-month periods unless there is the notice to cancel. The lease can be cancelled at any time by either party with 30 days’ notice prior to expiration of an applicable term. For the six months ended December 31, 2018 and 2017, the Company incurred $1,246 and $1,238, respectively.

XML

SHAREHOLDERS' EQUITY

6 Months Ended

Dec. 31, 2018

Equity [Abstract]

SHAREHOLDERS' EQUITY

9. SHAREHOLDERS' EQUITY

Series A Preferred Stock

The Company is authorized to issue 60,000,000 shares of Series A Preferred Stock at a par value of $0.0001.

Each Series A preferred share is convertible into 1,500 shares of common stock and has the voting rights of 1,000 shares of common stock.

As at December 31, 2018 and June 30, 2018, 5,000,000 shares of the Company's Series A Preferred Stock were issued and outstanding.

Common Stock

During the six months ended December 31, 2018, the Company issued 382,664,200 shares of common stock for conversion of debt and accrued interest of $28,973.

As at December 31, 2018 and June 30, 2018, 1,623,141,260 and 1,240,477,060 shares of the Company's common stock were issued and outstanding.

Stock payable

The Company had insufficient authorized shares as of June 30, 2017 and as a result, the Company had $105,000 in stock payable for which it is obligated to issue 55,000,000 shares of common stock for consulting services. During the year ended June 30, 2018 the company issued 30,000,000 common shares for cash of $200 and reduced common stock payable by $57,273.

As of December 31, 2018, the Company had $47,727 in stock payable for which it is obligated to issue 25,000,000 shares of common stock for consulting services.

On November 13, 2017, the Company entered into a consulting agreement with a third party for the term of 5 years with a consideration of an issuance of 40,000,000 shares of common stock valued at $20,000. The share shall be issued in two tranches with first tranche of 10,000,000 shares being due at signing of this agreement and an additional 30,000,000 shares are due on the 3 months anniversary of this agreement. During the year ended June 30, 2018, the Company issued 10,000,000 shares with a fair value of $5,000. As of December 31, 2018, the Company had $15,000 in stock payable for which it is obligated to issue 30,000,000 shares of common stock for consulting services.

XML

RELATED PARTY TRANSACTIONS

6 Months Ended

Dec. 31, 2018

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

10. RELATED PARTY TRANSACTIONS

In March 2016, the Company appointed current CEO and approved a base compensation package of $8,000 per month for CEO. As of December 31, 2018, and June 30, 2018, the Company recorded accrued salary of $272,000 and $224,000, respectively.

During the six months ended December 31, 2018 and 2017, the Company borrowed a total amount of $4,196 and $20,050 from Evergreen Venture Partners LLC (“EVP”), which the CEO is the majority owner, and repaid $9,594 and $6,571, respectively. This loan is a non-interest bearing and due on demand. As of December 31, 2018, and June 30, 2018, the Company owed EVP, a related party $82,689 and $88,087, respectively.

XML

EARNING (LOSS) PER SHARE

6 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

EARNING (LOSS) PER SHARE

11. EARNING (LOSS) PER SHARE The following is a reconciliation of the numerator and denominator used in the basic and diluted earnings per share ("EPS") calculations.

	Three Months Ended						Six months ended
	December 31,						December 31,
	2018			2017			2018			2017
Numerator:
Net income (loss)	$	407,055		$	(537,511	)	$	189,479		$	(944,144	)
Earnings allocated to participating securities		(451,958	)		-			(278,622	)		-
Income (loss) available to common stockholders	$	(44,903	)	$	(537,511	)	$	(89,143	)	$	(944,144	)
Denominator:
Weighted-average shares of common stock		1,330,983,536			944,991,968			1,285,730,298			805,777,397
Dilutive effect of convertible instruments		5,614,029,126			-			5,614,029,126			-
Dilutive effect of outstanding warrants		228,030,216			-			248,722,245			-
Diluted weighted-average of common stock		7,173,042,878			944,991,968			7,148,481,669			805,777,397
Net income (loss) per common share from:
Basic:	$	0.00		$	(0.00	)	$	0.00		$	(0.00	)
Diluted:	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

For the periods ended December 31, 2017, the convertible instruments are anti-dilutive and therefore, have been excluded from earnings (loss) per share.

For the periods ended December 31, 2018, diluted earnings per share is calculated using net income available to common stockholders divided by the diluted weighted average number of common shares outstanding during each period determined using the treasury stock method and the if-converted method.

XML

SUBSEQUENT EVENTS

6 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

12. SUBSEQUENT EVENTS

Subsequent to December 31, 2018, the Company issued 527,300,000 shares of common stock for conversion of debt and accrued interest of $25,448.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)

6 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions about the valuation and recognition of stock-based compensation expense, the valuation and recognition of derivative liability, valuation allowance for deferred tax assets and useful life of fixed assets.

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of AppYea and its subsidiaries. Intercompany transactions and balances have been eliminated.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The following table summarizes fair value measurements by level at December 31, 2018 and June 30, 2018, measured at fair value on a recurring basis:

December 31, 2018	Level 1		Level 2		Level 3		Total
Assets
None	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	-	$	-	$	566,519	$	566,519

June 30, 2018	Level 1		Level 2		Level 3		Total
Assets
None	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	-	$	-	$	1,016,865	$	1,016,865

XML

SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of fair value measurements of financial instruments on recurring basis

December 31, 2018	Level 1		Level 2		Level 3		Total
Assets
None	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	-	$	-	$	566,519	$	566,519

June 30, 2018	Level 1		Level 2		Level 3		Total
Assets
None	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	-	$	-	$	1,016,865	$	1,016,865

XML

FIXED ASSETS (Tables)

6 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of fixed assets

		December 31			June 30,
	2018			2018
Mobile applications	$	257,870		$	257,870
Accumulated depreciation		(257,070	)		(250,570	)
Fixed assets, net	$	800		$	7,300

XML

CONVERTIBLE LOANS (Tables)

6 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Schedule of convertible loans

	December 31,			June 30,
	2018			2018
March 2015 Note	$	-		$	-
November 2016 Note -1		150,000			150,000
Convertible notes - Issued in fiscal year 2018		188,996			195,614
Total convertible notes payable		338,996			345,614
Accrued interest		35,630			27,177
Less: Unamortized debt discount		(37,095	)		(81,968	)
Total convertible notes		337,531			290,823
Less: current portion of convertible notes		337,531			290,823
Long-term convertible notes	$	-		$	-

Schedule of warrants activity

	Warrants Outstanding
	Shares		Weighted Average Exercise Price
Outstanding, June 30, 2018		592,916,818	$	0.0004
Granted		-		-
Reset feature		-		-
Exercised		-		-
Forfeited/canceled		-		-
Outstanding, December 31, 2018		592,916,818	$	0.0004

Schedule of outstanding and exercisable warrants

Warrants Outstanding						Warrants Exercisable
Number of Shares		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Number of Shares		Weighted Average Exercise Price
	5,000,000		0.87	$	0.03		5,000,000	$	0.03
	193,181,818		3.79	$	0.0001		193,181,818	$	0.0001
	394,735,000		2.48	$	0.0002		394,735,000	$	0.0002
	592,916,818		2.90	$	0.0004		592,916,818	$	0.0004

XML

CONVERTIBLE LOANS - RELATED PARTY (Tables)

6 Months Ended

Dec. 31, 2018

Convertible Loans Related Party [Abstract]

Schedule of convertible loan-related party

	December 31,		June 30,
	2018		2018
Convertible notes - related party -Issued in fiscal year 2018		8,333		8,333
Total convertible notes payable		8,333		8,333
Accrued interest -related party		1,666		644
Less: Unamortized debt discount - related party		-		-
Total convertible notes		9,999		8,977
Less: current portion of convertible notes - related party		9,999		8,977
Long-term convertible notes	$	-	$	-

XML

DERIVATIVE LIABILITIES (Tables)

6 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of estimated fair values of the liabilities measured on a recurring basis

	Six months ended December 31, 2018			Year Ended June 30, 2018
Expected term		0.48 - 4.04 years			0.04 - 5.00 years
Expected average volatility		270%-451	%		147%-488	%
Expected dividend yield		-			-
Risk-free interest rate		2.36%-2.94	%		0.96%-2.73	%

Schedule of changes in the derivative liabilities

Fair Value Measurements Using Significant Observable Inputs (Level 3)
Balance - June 30, 2018	$	1,016,865
Settled due to conversion of debt		(95,021	)
Gain on change in fair value of the derivative		(355,325	)
Balance - December 31, 2018	$	566,519

XML

EARNING (LOSS) PER SHARE (Tables)

6 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Schedule of reconciliation of the numerator and denominator used in the basic and diluted earnings per share ("EPS")

	Three Months Ended						Six months ended
	December 31,						December 31,
	2018			2017			2018			2017
Numerator:
Net income (loss)	$	407,055		$	(537,511	)	$	189,479		$	(944,144	)
Earnings allocated to participating securities		(451,958	)		-			(278,622	)		-
Income (loss) available to common stockholders	$	(44,903	)	$	(537,511	)	$	(89,143	)	$	(944,144	)
Denominator:
Weighted-average shares of common stock		1,330,983,536			944,991,968			1,285,730,298			805,777,397
Dilutive effect of convertible instruments		5,614,029,126			-			5,614,029,126			-
Dilutive effect of outstanding warrants		228,030,216			-			248,722,245			-
Diluted weighted-average of common stock		7,173,042,878			944,991,968			7,148,481,669			805,777,397
Net income (loss) per common share from:
Basic:	$	0.00		$	(0.00	)	$	0.00		$	(0.00	)
Diluted:	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

XML

SIGNIFICANT ACCOUNTING POLICIES (Details) - Recurring basis - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Assets
Assets	$ 0	$ 0
Liabilities
Derivative liabilities	566,519	1,016,865
Level 1
Assets
Assets	0	0
Liabilities
Derivative liabilities	0	0
Level 2
Assets
Assets	0	0
Liabilities
Derivative liabilities	0	0
Level 3
Assets
Assets	0	0
Liabilities
Derivative liabilities	$ 566,519	$ 1,016,865

XML

GOING CONCERN AND LIQUIDITY (Detail Textuals) - USD ($)	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Going Concern And Liquidity [Abstract]
Cash	$ 2,064	$ 47,196	$ 10,087	$ 42,567
Current liabilities	1,538,959	$ 1,904,064
Working capital deficit	$ (1,536,895)

XML

FIXED ASSETS - Fixed assets balance of mobile application software (Details) - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Mobile applications	$ 257,870	$ 257,870
Accumulated depreciation	(257,070)	(250,570)
Fixed assets, net	$ 800	$ 7,300

XML

FIXED ASSETS (Detail Textuals) - USD ($)	3 Months Ended	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 7,936	$ 6,500	$ 18,744

XML

CONVERTIBLE LOANS (Details) - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Short-term Debt [Line Items]
Total convertible notes payable	$ 338,996	$ 345,614
Accrued interest	35,630	27,177
Less: Unamortized debt discount	(37,095)	(81,968)
Total convertible notes	337,531	290,823
Less: current portion of convertible notes	337,531	290,823
Long-term convertible notes	0	0
Convertible promissory note payable | March 2015 Note
Short-term Debt [Line Items]
Total convertible notes payable	0	0
Accrued interest	454	454
Convertible promissory note payable | November 2016 Note -1
Short-term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Convertible promissory note payable | Convertible notes - Issued in fiscal year 2018
Short-term Debt [Line Items]
Total convertible notes payable	$ 188,996	$ 195,614

XML

CONVERTIBLE LOANS (Details 1)	6 Months Ended
	Dec. 31, 2018 $ / shares shares
Warrant Outstanding, Shares
Outstanding, June 30, 2018 | shares	592,916,818
Granted | shares	0
Reset feature | shares	0
Exercised | shares	0
Forfeited/canceled | shares	0
Outstanding, December 31, 2018 | shares	592,916,818
Warrant Outstanding, Weighted Average Exercise Price
Outstanding, June 30, 2018 | $ / shares	$ 0.0004
Granted | $ / shares	0.0000
Reset feature | $ / shares	0.0000
Exercised | $ / shares	0.0000
Forfeited/canceled | $ / shares	0.0000
Outstanding, December 31, 2018 | $ / shares	$ 0.0004

XML

CONVERTIBLE LOANS (Details 2) - $ / shares	6 Months Ended
	Dec. 31, 2018	Jun. 30, 2018
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number of Shares	592,916,818	592,916,818
Warrants Outstanding, Weighted Average Exercise Price	$ 0.0004	$ 0.0004
Warrant One
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number of Shares	5,000,000
Warrants Outstanding, Weighted Average Remaining Contractual life (in years)	10 months 13 days
Warrants Outstanding, Weighted Average Exercise Price	$ 0.03
Warrants Exercisable, Number of Shares	5,000,000
Warrants Exercisable, Weighted Average Exercise Price	$ 0.03
Warrant Two
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number of Shares	193,181,818
Warrants Outstanding, Weighted Average Remaining Contractual life (in years)	3 years 9 months 15 days
Warrants Outstanding, Weighted Average Exercise Price	$ 0.0001
Warrants Exercisable, Number of Shares	193,181,818
Warrants Exercisable, Weighted Average Exercise Price	$ 0.0001
Warrant Three
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number of Shares	394,735,000
Warrants Outstanding, Weighted Average Remaining Contractual life (in years)	2 years 5 months 23 days
Warrants Outstanding, Weighted Average Exercise Price	$ 0.0002
Warrants Exercisable, Number of Shares	394,735,000
Warrants Exercisable, Weighted Average Exercise Price	$ 0.0002
Warrant Four
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number of Shares	592,916,818
Warrants Outstanding, Weighted Average Remaining Contractual life (in years)	2 years 10 months 24 days
Warrants Outstanding, Weighted Average Exercise Price	$ 0.0004
Warrants Exercisable, Number of Shares	592,916,818
Warrants Exercisable, Weighted Average Exercise Price	$ 0.0004

XML

CONVERTIBLE LOANS (Detail Textuals)	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 25, 2018 USD ($) Day $ / shares shares	Nov. 15, 2016 USD ($) Day Month Agreement $ / shares shares	Dec. 31, 2018 USD ($) $ / shares	Dec. 31, 2017 USD ($)	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($)	Jun. 30, 2018 USD ($) $ / shares	Jun. 30, 2017 USD ($)	Jan. 26, 2017 USD ($)
Short-term Debt [Line Items]
Amortization of discount, included in interest expense					$ 44,873	$ 169,442
Convertible promissory note payable, issued	$ 78,947		$ 28,973		28,973
Interest rate	5.00%
Number of trading days for lowest traded price | Day	20
Value of lowest conversion price | $ / shares	$ 0.0002
Outstanding principle balance of debt			337,531		337,531		$ 290,823
Accrued interest			35,630		35,630		27,177
Convertible loans and accrued interest, unamortized discounts (in dollars)			37,095		$ 37,095		81,968
Number of notes converted into common stock | shares					382,664,200
Amount of derivative liability credited to additional paid in capital					$ 95,021
Change in fair value of derivative liabilities			486,086	$ (215,751)	355,325	$ (349,988)
Total convertible notes payable			337,531		337,531		$ 290,823
Terms of rang							6 months
Amount of convertible notes default			$ 116,666		116,666
Original issue discounts and financing costs					38,447
Proceeds from convertible notes payable, net of original issue discounts					$ 142,167
Warrant or right exercisable of common stock Shares | shares	394,735,000
Exercise price of warrants | $ / shares			$ 0.0004		$ 0.0004		$ 0.0004
Number of increased in reset features warrants | shares					0
Warrants exercisable common stock per share | $ / shares					$ 0.0000
Total convertible notes payable			$ 338,996		$ 338,996		$ 345,614
Warrant Two
Short-term Debt [Line Items]
Exercise price of warrants | $ / shares			$ 0.0001		$ 0.0001
Warrants Exercisable, Number of Shares | shares					193,181,818
Convertible promissory note payable | Minimum
Short-term Debt [Line Items]
Percentage of debt instrument redemption					115.00%
Convertible promissory note payable | Maximum
Short-term Debt [Line Items]
Percentage of debt instrument redemption					150.00%
Convertible promissory note payable | March 2015 Note
Short-term Debt [Line Items]
Accrued interest			$ 454		$ 454		454
Total convertible notes payable			0		0		0
Convertible promissory note payable | November 2016 Note -1
Short-term Debt [Line Items]
Total convertible notes payable			150,000		150,000		150,000
Convertible promissory note payable | November 2016 Note -1 | Greentree Financial Group, Inc
Short-term Debt [Line Items]
Convertible promissory note payable, issued		$ 250,000
Interest rate		12.00%
Percentage of issuance discount on note		10.00%
Discount percentage of lowest traded price		55.00%
Number of trading days for lowest traded price | Day		10
Value of lowest conversion price | $ / shares		$ 0.0001
Percentage of prepayment penalty with each promissory note conversion		10.00%
Notes Issued		$ 100,000
Number of common stock called by warrants | shares		5,000,000
Note convertible, threshold consecutive period | Month		6
Conversion features, value		$ 1,500
Number of agreement | Agreement		4
Exercise price of warrants | $ / shares		$ 0.03
Convertible promissory note payable | November 2016 Note -2
Short-term Debt [Line Items]
Convertible promissory note payable, issued								$ 75,000	$ 75,000
Convertible promissory note payable | Convertible notes - Issued in fiscal year 2018
Short-term Debt [Line Items]
Convertible promissory note payable, issued							$ 180,614
Value of lowest conversion price | $ / shares							$ 0.0002
Total convertible notes payable			$ 188,996		$ 188,996		$ 195,614
Discount rate of conversion price if less than $0.01							15.00%
Principal amount							$ 15,000
Penalty amount							$ 15,000
Convertible promissory note payable | Convertible notes - Issued in fiscal year 2018 | Minimum
Short-term Debt [Line Items]
Interest rate							5.00%
Discount percentage of lowest traded price							35.00%
Terms of rang							6 months
Discount rate of conversion							45.00%
Convertible promissory note payable | Convertible notes - Issued in fiscal year 2018 | Maximum
Short-term Debt [Line Items]
Interest rate							12.00%
Discount percentage of lowest traded price							45.00%
Terms of rang							12 months
Discount rate of conversion							60.00%

XML

CONVERTIBLE LOANS (Detail Textuals 1)	1 Months Ended	6 Months Ended		12 Months Ended
	Jun. 25, 2018 USD ($) Day $ / shares shares	Dec. 31, 2018 USD ($) $ / shares	Dec. 31, 2017 USD ($)	Jun. 30, 2018 USD ($) $ / shares
Short-term Debt [Line Items]
Principal amount of promissory Note	$ 78,947	$ 28,973
Interest rate	5.00%
Conversion price | $ / shares	$ 0.0002
Number of trading days for lowest traded price | Day	20
Exercise price of warrants | $ / shares		$ 0.0004		$ 0.0004
Fair value of derivative liability				$ 9,371
Derivative liability recognized as debt discount			$ 235,000
Derivative loss		$ 1,038
Warrant
Short-term Debt [Line Items]
Fair value of derivative liability				965,401
Derivative liability recognized as debt discount				277,167
Derivative loss				$ 688,234
Bellridge Capital L.P | Warrant
Short-term Debt [Line Items]
Additional shares of common stock | shares	394,735,000
Description of notice for agreement	If the Company prepays the note on or before 90 days following the date of the note, the Company shall be required to pay 115%, multiplied by the sum of the outstanding principal of the note, plus all accrued and unpaid interest and default interest if any. If the Company prepays the note during the period beginning 91 days and ending 180 days from the issue date of the note, the Company shall be required to pay 120% multiplied by the sum of the then outstanding principal amount of the note, plus accrued and unpaid interest and default interest, if any. If the Company prepays the note during the period beginning after 180 days from the issue date of the note, the Company shall be required to pay 125% multiplied by the sum of the then outstanding principal amount of the note, plus accrued and unpaid interest and default interest, if any.
Term of warrant	3 years
Exercise price of warrants | $ / shares	$ 0.0002

XML

CONVERTIBLE LOANS - RELATED PARTY (Details) - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Convertible Loans Related Party [Abstract]
Convertible notes - related party -Issued in fiscal year 2018	$ 8,333	$ 8,333
Total convertible notes payable	8,333	8,333
Accrued interest -related party	1,666	644
Less: Unamortized debt discount - related party	0	0
Total convertible notes	9,999	8,977
Less: current portion of convertible notes - related party	9,999	8,977
Long-term convertible notes	$ 0	$ 0

XML

CONVERTIBLE LOANS - RELATED PARTY (Detail Textuals) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Short-term Debt [Line Items]
Amortization of debt discounts	$ 44,873	$ 171,514
Proceeds from issuance of promissory notes			$ 8,333
Term of promissory notes			6 months
Annual interest rate			8.00%
Discounted conversion rate on average closing price			45.00%
Fair value of derivative liability			$ 9,371
Derivative liability recognized as debt discount to notes	8,333
Derivative loss	1,038
CONVERTIBLE LOANS - RELATED PARTY
Short-term Debt [Line Items]
Amortization of debt discounts	$ 0	$ 2,072

XML

DERIVATIVE LIABILITIES (Details)	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Jun. 30, 2018
Expected dividend yield
Derivative [Line Items]
Derivative liability, measurement input	0	0
Minimum | Expected term
Derivative [Line Items]
Expected term	5 months 23 days	15 days
Minimum | Expected average volatility
Derivative [Line Items]
Derivative liability, measurement input	270	147
Minimum | Risk-free interest rate
Derivative [Line Items]
Derivative liability, measurement input	2.36	0.96
Maximum | Expected term
Derivative [Line Items]
Expected term	4 years 15 days	5 years
Maximum | Expected average volatility
Derivative [Line Items]
Derivative liability, measurement input	451	488
Maximum | Risk-free interest rate
Derivative [Line Items]
Derivative liability, measurement input	2.94	2.73

XML

DERIVATIVE LIABILITIES (Details 1)	6 Months Ended
	Dec. 31, 2018 USD ($)
Derivative Liabilities Roll Forward
Balance - June 30, 2018	$ 1,016,865
Settled due to conversion of debt	(95,021)
Gain on change in fair value of the derivative	(355,325)
Balance - December 31, 2018	$ 566,519

XML

DERIVATIVE LIABILITIES (Detail Textuals) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregate (gain) loss on derivatives	$ (486,086)	$ 215,751	$ (355,325)	$ 349,988

XML

COMMITMENTS AND CONTINGENCIES (Detail Textuals) - USD ($)		1 Months Ended			6 Months Ended
	Oct. 02, 2017	Oct. 17, 2017	Dec. 31, 2016	Jan. 30, 2013	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Commitments And Contingencies [Line Items]
Lease and rental expense				$ 200	$ 1,246	$ 1,238
Leases, term of contract				3 months
Description of lease term				three-month periods unless there is the notice to cancel. The lease can be cancelled at any time by either party with 30 days' notice prior to expiration of an applicable term.
Contract agreement | M Endeavors, Llc
Commitments And Contingencies [Line Items]
Term of agreement for marketing services to Doctors office, clinic and hospitals			5 years
Additonal term of agreement on renewation			12 months
Monthly fee and expenses paid			$ 8,000
Accrued expenses					75,000		$ 75,000
Contract agreement | Big Dreams Ventures, Llc
Commitments And Contingencies [Line Items]
Term of agreement for marketing services to Doctors office, clinic and hospitals			5 years
Additonal term of agreement on renewation			12 years
Monthly fee and expenses paid			$ 10,000
Accrued expenses					105,250		105,250
Contract agreement | Pacific Pain & Regenerative Medicine
Commitments And Contingencies [Line Items]
Monthly fee and expenses paid	$ 3,000
Accrued expenses					21,000		21,000
Number of PGX tests collected per week	5
Number of PGX tests collected per month	$ 20
Placement agreement | Wellington Shields $ Co.
Commitments And Contingencies [Line Items]
Accrued expenses					$ 60,000		$ 60,000
Agreement, value		$ 30,000,000
Percentage of proceeds from agreement		8.00%
Percentage of total shares outstanding		3.00%
Agreement signing amount, paid		$ 15,000
Agreement, monthly payment		$ 10,000

XML

SHAREHOLDERS' EQUITY (Detail Textuals) - USD ($)		6 Months Ended		12 Months Ended
	Nov. 13, 2017	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Shareholders Equity [Line Items]
Convertible preferred stock, shares authorized		60,000,000		60,000,000
Convertible preferred stock, par value (in dollars per share)		$ 0.0001		$ 0.0001
Convertible preferred stock, number of shares issued on conversion		1,500
Convertible preferred stock, voting rights		voting rights of 1,000 shares of common stock
Convertible preferred stock, shares issued		5,000,000		5,000,000
Convertible preferred stock, shares outstanding		5,000,000		5,000,000
Shares of common stock for conversion of debt		382,664,200
Issuance of common stock for conversion of debt and accrued interest		$ 28,973	$ 145,039
Common stock, shares issued		1,623,141,260		1,240,477,060
Common stock, shares outstanding		1,623,141,260		1,240,477,060
Amount of Stock payable, common shares		$ 47,727			$ 105,000
Number of shares payable for service		25,000,000			55,000,000
Number of common stock issued for services				30,000,000
Amount of common stock issued for cash				$ 200
Stock issued period for common stock payable				$ 57,273
Due on signing of agreement
Shareholders Equity [Line Items]
Number of shares payable for service				10,000,000
Amount of common stock issued for services				$ 5,000
3 months anniversary of agreement
Shareholders Equity [Line Items]
Number of shares payable for service	30,000,000
Consulting agreement
Shareholders Equity [Line Items]
Amount of Stock payable, common shares		$ 15,000
Number of shares payable for service	40,000,000
Initial term of Management Services Agreement	5 years
Amount of common stock issued for services	$ 20,000
Stock payable, common shares (in shares)		30,000,000

XML

RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)	1 Months Ended	6 Months Ended
	Mar. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Related Party Transaction [Line Items]
Accrued salaries		$ 272,000		$ 224,000
Total amount borrowed		4,196	$ 20,050
Repayment to EVP		9,594	$ 6,571
Amount owed to Evergreen Venture Partners LLC ("EVP")		$ 82,689		$ 88,087
CEO
Related Party Transaction [Line Items]
Base compensation package per month	$ 8,000

XML

EARNING (LOSS) PER SHARE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Numerator:
Net income (loss)	$ 407,055	$ (537,511)	$ 189,479	$ (944,144)
Earnings allocated to participating securities	(451,958)	0	(278,622)	0
Income (loss) available to common stockholders	$ (44,903)	$ (537,511)	$ (89,143)	$ (944,144)
Denominator:
Weighted-average shares of common stock	1,330,983,536	944,991,968	1,285,730,298	805,777,397
Dilutive effect of convertible instruments	5,614,029,126	0	5,614,029,126	0
Dilutive effect of outstanding warrants	228,030,216	0	248,722,245	0
Diluted weighted-average of common stock	7,173,042,878	944,991,968	7,148,481,669	805,777,397
Net income (loss) per common share from:
Basic:	$ 0.00	$ (0.00)	$ 0.00	$ (0.00)
Diluted:	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)

XML

SUBSEQUENT EVENTS (Detail Textuals) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 18, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Shares of common stock for conversion of debt		382,664,200
Subsequent Event
Subsequent Event [Line Items]
Shares of common stock for conversion of debt	527,300,000
Accrued interest	$ 25,448